| 纯度 | > 95 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD80 |
| Uniprot No | P33681 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-242aa |
| 氨基酸序列 | VIHVTKEVKEVATLSCGHNVSVEELAQTRIYWQKEKKMVLTMMSGDMNIW PEYKNRTIFDITNNLSIVILALRPSDEGTYECVVLKYEKDAFKREHLAEV TLSVKADFPTPSISDFEIPT SNIRRIICSTSGGFPEPHLSWLENGEEL NAINTTVSQDPETELYAVSSKLDFNMTTNHSF MCLIKYGHLRVNQTFN WNTTKQEHFPDN |
| 预测分子量 | 50 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD80重组蛋白的3篇模拟参考文献示例(文献为虚构，仅供格式参考)：
---
1. **文献名称**：Crystal structure of recombinant human CD80 and its interaction with CTLA-4
**作者**：Smith A, et al.
**摘要**：本研究通过X射线晶体学解析了重组人CD80蛋白的胞外结构域三维结构，并分析其与CTLA-4的结合模式。实验表明，重组CD80在体外能有效阻断CTLA-4介导的T细胞抑制信号，为免疫检查点抑制剂设计提供结构基础。
---
2. **文献名称**：Recombinant CD80 enhances antitumor immunity in a murine melanoma model
**作者**：Chen L, et al.
**摘要**：通过大肠杆菌表达系统制备重组CD80蛋白，并评估其作为肿瘤疫苗佐剂的潜力。在黑色素瘤小鼠模型中，CD80联合肿瘤抗原显著增强CD8+ T细胞活化和肿瘤消退，提示其免疫治疗应用前景。
---
3. **文献名称**：Functional characterization of glycosylated CD80 recombinant protein expressed in HEK293 cells
**作者**：Wang Y, et al.
**摘要**：利用HEK293细胞表达糖基化修饰的重组CD80蛋白，证实其与CD28的结合亲和力高于原核表达产物。体外实验显示，糖基化CD80可更有效促进T细胞增殖与IL-2分泌，强调翻译后修饰对其功能的重要性。
---
注：以上文献及作者为模拟内容，实际引用请通过PubMed或Google Scholar检索真实研究。
CD80. also known as B7-1. is a transmembrane glycoprotein belonging to the immunoglobulin superfamily. It is primarily expressed on antigen-presenting cells (APCs), such as dendritic cells, B cells, and macrophages, and plays a pivotal role in regulating T-cell activation and immune responses. CD80 interacts with two key receptors on T cells: CD28. which provides a co-stimulatory signal for T-cell activation, and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), which delivers an inhibitory signal to dampen immune activity. This dual binding capability positions CD80 as a critical checkpoint modulator in adaptive immunity, balancing immune activation and tolerance.
Recombinant CD80 protein is engineered using mammalian expression systems (e.g., CHO or HEK293 cells) to produce soluble, functional extracellular domains. It typically retains the IgV and IgC domains required for receptor binding, often fused with Fc tags or His tags for purification and detection. Researchers utilize this protein to study T-cell/APC interactions, screen therapeutic agents (e.g., CTLA-4 inhibitors like ipilimumab), and develop in vitro models of autoimmune diseases or cancer immunotherapy. Its activity is validated through binding assays (ELISA, SPR) and functional studies measuring T-cell proliferation or cytokine release.
The development of recombinant CD80 has advanced immunotherapy research, particularly in understanding immune checkpoint pathways and optimizing biologics targeting co-stimulatory/inhibitory signals. Its applications extend to vaccine development, autoimmune disorder studies, and combination therapies with PD-1/PD-L1 inhibitors.
×
